ArticleEuropean heart journal. Cardiovascular pharmacotherapy2023
Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI).
Article in European heart journal. Cardiovascular pharmacotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- β-blocker and clinical outcomes in patients after myocardial infarction: a systematic review and meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- The prognostic value of global longitudinal strain in patients with myocardial infarction and preserved ejection fraction: a prespecified substudy of the REDUCE-AMI trial.European heart journal. Cardiovascular Imaging · 2025Trial
- Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function-a prespecified substudy from REDUCE-AMI.European heart journal. Cardiovascular pharmacotherapy · 2025Trial
- Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial.European heart journal. Acute cardiovascular care · 2024Trial
- Exploring risk factors for new-onset atrial fibrillation in elderly patients with myocardial infarction based on serum NT-proBNP, RDW, Hcy, and clinical parameters: an exploratory study using LASSO-logistic regression.Frontiers in cardiovascular medicine · 2026Article
- New Zealand Electronic Health Data for Cardiovascular Research: A Review.Clinical epidemiology · 2026Review
- Chronic β-Blockade and Systemic Homeostasis: Molecular Integration of Cardiorenal and Immune Pathways, a Narrative Review.Biomolecules · 2025Review
- Different aspects of pharmacological heart failure treatment.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- A multimodal nomogram for predicting disease progression in diabetic patients with coronary artery disease: integrating clinical, ultrasound, and angiographic data.BMC cardiovascular disorders · 2025Article
- Prevention is the key.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- Identifying target populations to align with decision-makers' needs.American journal of epidemiology · 2024Article
- Use cases of registry-based randomized controlled trials-A review of the registries' contributions and constraints.Clinical and translational science · 2024Review
- Article
- Prospective benchmarking of an observational analysis in the SWEDEHEART registry against the REDUCE-AMI randomized trial.European journal of epidemiology · 2024Article
- The perpetual need of randomized clinical trials: challenges and uncertainties in emulating the REDUCE-AMI trial.European journal of epidemiology · 2024Article
- Predictors of Premature Mortality Following Coronary Artery Bypass Grafting: An Iranian Single-Centre Study.Healthcare (Basel, Switzerland) · 2023Article
- Randomized evaluation of routine beta-blocker therapy after myocardial infarction quality of life (RQoL): design and rationale of a multicentre, prospective, randomized, open, blinded endpoint study.European heart journal open · 2023Article
- Impact of Hospital Ward Acoustic Design on Postoperative Recovery of Patients with Acute Myocardial Infarction.Noise & healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 4 countries.
Funding
Abstract
aimsMost trials showing benefit of beta-blocker treatment after myocardial infarction (MI) included patients with large MIs and are from an era before modern biomarker-based MI diagnosis and reperfusion treatment. The aim of the randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI) trial is to determine whether long-term oral beta-blockade in patients with an acute MI and preserved left ventricular ejection fraction (EF) reduces the composite endpoint of death of any cause or recurrent MI. METHODS AND
resultsIt is a registry-based, randomized, parallel, open-label, multicentre trial performed at 38 centres in Sweden, 1 centre in Estonia, and 6 centres in New Zealand. About 5000 patients with an acute MI who have undergone coronary angiography and with EF ≥ 50% will be randomized to long-term treatment with beta-blockade or not. The primary endpoint is the composite endpoint of death of any cause or new non-fatal MI. There are several secondary endpoints, including all-cause death, cardiovascular death, new MI, readmission because of heart failure and atrial fibrillation, symptoms, functional status, and health-related quality of life after 6-10 weeks and after 1 year of treatment. Safety endpoints are bradycardia, AV-block II-III, hypotension, syncope or need for pacemaker, asthma or chronic obstructive pulmonary disease, and stroke.
conclusionThe results from REDUCE-AMI will add important evidence regarding the effect of beta-blockers in patients with MI and preserved EF and may change guidelines and clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.